Scarica l'app Stockscreener
44.74
2.31%
-1.06
Dopo l'orario di chiusura:
44.47
-0.27
-0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novo Nordisk Adr Borsa (NVO) Ultime notizie
2 Ways to Play the Big Pharma Patent Cliff - Investing.com
Novo Nordisk A/S stock (DK0062498333): Wegovy data and earnings outlook keep GLP-1 race in focus - AD HOC NEWS
Novo Nordisk Highlights New Wegovy Pill Data - Sahm
Novo Nordisk A/ S stock (DK0060534915): Up 1.29% to $47 amid recovery trend - AD HOC NEWS
Novo Nordisk Oral Wegovy Data Sharpen Obesity Opportunity And Valuation Gap - Sahm
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk A/ S stock (DK0062498333): Wegovy data fuels 3% premarket surge - AD HOC NEWS
Amazon Pharmacy Deal Puts Novo Nordisk Access And Valuation In Focus - Sahm
Novo Nordisk A/S stock (DK0060534915): Weight-loss and diabetes leader faces new pricing pressures - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Q1 beats and 2026 outlook lift shares on Nasdaq Copenhagen an - AD HOC NEWS
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook - Sahm
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years - Sahm
Market news - investments.halifax.co.uk
Shares in Novo Nordisk jump after Wegovy pill sales smash forecasts - Sharecast.com
Novo Nordisk Explores New Growth In Alcohol Use Disorder And Obesity - Sahm
FDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - Sahm
European ADRs Jumped In US Trading, Led By Novo Nordisk - Finimize
Novo Nordisk’s Oral Ozempic And Pediatric Plans Reframe GLP-1 Opportunity - Sahm
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Novo Nordisk (NYSE: NVO) details DKK 3.4B B-share repurchases - Stock Titan
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients - Sahm
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to sustain long-t - AD HOC NEWS
[6-K] NOVO NORDISK A S Current Report (Foreign Issuer) | NVO SEC FilingForm 6-K - Stock Titan
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to unlock new upside? - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Is obesity drug dominance strong enough to sustain growth? - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Is its obesity drug dominance strong enough to unlock new ups - AD HOC NEWS
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):